Alnylam

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it. 

The court found that the university had failed to demonstrate that one of its researchers had collaborated with the IP's inventors and therefore is not entitled to co-inventorship.

The firm also said it aims to soon begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria type 1.

The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.

The proceeds will be used to advance its drug candidates and for general corporate purposes.

The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.

Advances in human genetics and siRNA delivery have helped drive the programs, according to company officials.

Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.

The therapy is the company's first to feature an optimized version of its GalNAc conjugate delivery technology.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.